You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Medtronic
Express Scripts
McKesson
AstraZeneca

Last Updated: May 31, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,501,164


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,501,164
Title:Nicotine lozenge compositions
Abstract: The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.
Inventor(s): Chen; Li-Lan (Parsippany, NJ)
Assignee: GlaxoSmithKline, LLC (Philadelphia, PA)
Application Number:12/990,049
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 8,501,164

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-001 May 18, 2009 OTC Yes No   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 022360-002 May 18, 2009 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,501,164

PCT Information
PCT FiledApril 30, 2009PCT Application Number:PCT/US2009/042190
PCT Publication Date:November 05, 2009PCT Publication Number: WO2009/134947

International Family Members for US Patent 8,501,164

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 071420   Start Trial
Australia 2009243065   Start Trial
Brazil PI0911847   Start Trial
Canada 2723011   Start Trial
Chile 2009001025   Start Trial
China 102076362   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
AstraZeneca
Mallinckrodt
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.